Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer
Status:
Completed
Trial end date:
2020-11-04
Target enrollment:
Participant gender:
Summary
The purposes of this study are:
1. To determine the dose limiting toxicity (DLT) and the maximum tolerated dose (MTD)
weekly of topotecan in combination with standard dose gefitinib in patients with
relapsed, platinum-resistant, ovarian, peritoneal or fallopian tube cancers that are
epidermal growth factor receptor (EGF-R) positive (>/= 1+).
2. To determine the response rate and response duration in this patient population treated
with the maximum tolerated dose (MTD) of topotecan administered on a weekly schedule in
combination with standard dose gefitinib, given by way of the mouth (PO) daily.